Clinical trial
TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment
NCT00144417 · Centers for Disease Control and Prevention, U.S. Fed · Completed
Key facts
| NCT number | NCT00144417 |
|---|---|
| Title | TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment |
| Official title | TBTC Study 28: Evaluation of a Moxifloxacin-based, Isoniazid-sparing Regimen for Tuberculosis Treatment |
| Lead sponsor | Centers for Disease Control and Prevention, U.S. Fed |
| Collaborators | Global Alliance for TB Drug Development Bayer Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Tuberculosis |
| Intervention type | Drug |
| Interventions | Moxifloxacin (with rifampin, pyrazinamide, and ethambutol), isoniazid |
| Enrollment | 433 |
| Start date | Feb 1, 2006 |
| Primary completion | Jun 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Sep 5, 2005 |
| Last update posted | Aug 3, 2011 |
| Countries | Brazil, Canada, South Africa, Spain, Uganda, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: